Medication Effectiveness with the Use of Tumor Necrosis Factor Inhibitors Among Texas Medicaid Patients Diagnosed with Rheumatoid Arthritis

BACKGROUND: Adalimumab (Humira [ADA]), etanercept (Enbrel [ETN]), and infliximab (Remicade [IFX]) are tumor necrosis factor (TNF) inhibitors indicated for the treatment of a variety of disorders. While their effectiveness has not been directly compared in a clinical trial, results from the majority...

Descripción completa

Detalles Bibliográficos
Autores principales: Oladapo, Abiola, Barner, Jamie C., Lawson, Kenneth A., Novak, Suzanne, Rascati, Karen L., Richards, Kristin M., Harrison, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437715/
https://www.ncbi.nlm.nih.gov/pubmed/24967519
http://dx.doi.org/10.18553/jmcp.2014.20.7.657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437715/
https://www.ncbi.nlm.nih.gov/pubmed/24967519
http://dx.doi.org/10.18553/jmcp.2014.20.7.657

Ejemplares similares